The current analyst sentiment for Henry Schein, Inc. (HSIC) indicates a balanced outlook with a mix of recommendations. The company, operating globally in the healthcare products and services sector, continues to maintain a strong position in the market. However, the prevalence of 'Hold' ratings suggests a cautious approach among analysts. Investors will need to consider both the growth potential and the inherent risks in this sector.
The latest analyst recommendations for HSIC, as of December 1, 2025, show a trend leaning towards caution, with 'Hold' being the most prominent recommendation. The following table highlights the current distribution of analyst ratings:
| Recommendation | Count | Score Bar |
|---|---|---|
| Strong Buy | 4 | |
| Buy | 2 | |
| Hold | 9 | |
| Sell | 1 | |
| Strong Sell | 0 |
The sentiment for Henry Schein, Inc. has shown stability over recent months with a consistent hold on 'Hold' ratings. Despite some fluctuations in 'Strong Buy' recommendations, the overall sentiment remains cautious with a steady 'Hold' category presence.
Analyzing the percentage trends over recent months shows an insightful shift in the composition of analyst recommendations for Henry Schein, Inc. Overall, there's been a slight movement from 'Buy' towards 'Hold' and 'Strong Buy'.
Recent analyst recommendations indicate a maintenance of existing ratings, with no significant upgrades or downgrades, suggesting stability in market views on Henry Schein, Inc. The table below lists the latest analysis:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-11-05 | Underweight | Underweight | Morgan Stanley |
| 2025-11-05 | Equal Weight | Equal Weight | Wells Fargo |
| 2025-11-05 | Overweight | Overweight | JP Morgan |
| 2025-11-05 | Outperform | Outperform | Evercore ISI Group |
| 2025-11-05 | Outperform | Outperform | Barrington Research |
Over the months, some analysts have changed their views on Henry Schein, Inc., indicating occasional shifts in market perspectives. The adjustments showcase a mix of upgrades and downgrades in outlook for the company.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-08-26 | Outperform | In Line | Evercore ISI Group |
| 2025-07-25 | Hold | Buy | Stifel |
| 2025-07-14 | Neutral | Outperform | Baird |
| 2025-01-06 | Buy | Underperform | B of A Securities |
| 2024-07-22 | Outperform | Neutral | Baird |
The analysis of Henry Schein, Inc.'s stock ratings reveals a predominantly cautious stance among analysts, as reflected in the high 'Hold' scores. This sentiment suggests a conservative outlook with no major uptrends anticipated in the near term. There is a mixture of opinions, with some optimism showcased through upgrades, yet an underlying hesitance is prevalent. The minor increase in 'Strong Buy' points towards a potential upward reevaluation of the company's market performance. Overall, stability seems to characterize the analyst viewpoint, with confidence maintained at moderate levels.
Henry Schein, Inc. exhibits a stable but cautious analyst sentiment, underscored by the prevalence of 'Hold' ratings. The healthcare sector dynamics offer growth opportunities, but also present inherent challenges and uncertainties. Investors should weigh these factors meticulously. Recent upgrades indicate pockets of optimism, but substantial uplifts in stock price may require new catalysts. Continued observation of market trends, competitive positioning, and sectoral shifts is recommended for potential investors.